Expectations trend
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsNYSEIndustrialsSpecialty Business ServicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RHLD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete acquisitions to enhance growth | A supporting condition in Resolute Holdings Management, Inc.'s published investment case. The stated target is complete at least one material acquisition by end 2026. | Intact | no material acquisitions completed by end 2026 | Material agreement entered May 2026 vs target by end 2026 May 2026 8-K reports entry into a material agreement (M&A activity), confirming acquisition progress. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is an acquisition-led growth story with a profitability component, rather than a clearly durable compounder today. The thesis is on watch: recent results are neutral, but performance has been below the industry cohort and management execution is assessed as volatile.
RHLD is described as cheap versus peers, though confidence in that valuation assessment is low. The evidence says weak execution quality is the main source of fragility, not a combination of expensive valuation, weak execution, and turbulent conditions; it does not specify exactly what operating expectations are priced in.
Near term, management has delivered on its stated profitability priority: fee-related earnings per share stayed at $0.69 in both recent quarters as management fees increased. Acquisitions support the growth plan, but the large acquisition outlay and sharp rise in long-term debt make capital allocation and balance-sheet management important to watch. A guidance cut on the next call is a stated risk, while the sector backdrop remains a headwind.
Over the next 1 to 3 years, the thesis depends on continued organic fee growth, profitable integration of acquisitions, and effective debt management. Near-term sector signals also matter: continued strength from CTAS, CPRT, and ROL could support Industrials sentiment, while missed results or lower guidance from those companies could remove that support. RHLD’s next guidance update is another key swing factor.
The 1 to 3 year view is a watch-stage growth thesis with some evidence of fee-based profitability, but execution, acquisitions, debt, and sector conditions remain meaningful risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage capital allocation to support growth and financial health |
| Capital allocation is being managed despite some financial obligations. |
| Intact |
| capital structure deteriorates causing liquidity stress |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Increase net income to at least $61.5M in 2026-Q1 | Resolute Holdings improved net income from -$3.4M in 2025-Q1 to $61.5M in 2026-Q1. | Intact | net income falls below $61.5M in 2026-Q1 | Net income: $-12.4M FY2026-Q2; GAAP. Published target: >=61500000 USD net income. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-12,400,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.